TriangleNCT02002598 · OUTCOME
Progression Free Survival (PFS)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- Months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 6.5 Years
What was measured
PFS is defined as the duration of time from start of study treatment to time of progression or death, whichever occurs first.
Groups in this outcome
CFZ With Bendamustine and Dexamethasone
First participant received: CFZ 27mg/m\^2, Bendamustine 70mg/m\^2, Dexamethasone 20mg; Second participant received: CFZ 36mg/m\^2, Bendamustine 70mg/m\^2, Dexamethasone 20mg; Third participant received: CFZ 36mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg; Fourth participant received: CFZ 45mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg; Fifth participant and all other participants received: CFZ 56mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg. Data was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.
| Group | Source count |
|---|---|
| CFZ With Bendamustine and Dexamethasone | 19 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CFZ With Bendamustine and Dexamethasone | 77 | Not reported | 34.5 | NA | The upper limit is not applicable due an to insufficient number of participants with events. |
Complete source fields
- classes
- categories
- measurements
- comment
- The upper limit is not applicable due an to insufficient number of participants with events.
- group Id
- OG000
- lower Limit
- 34.5
- upper Limit
- NA
- value
- 77
- denoms
- counts
- group Id
- OG000
- value
- 19
- units
- Participants
- description
- PFS is defined as the duration of time from start of study treatment to time of progression or death, whichever occurs first.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- First participant received: CFZ 27mg/m\^2, Bendamustine 70mg/m\^2, Dexamethasone 20mg; Second participant received: CFZ 36mg/m\^2, Bendamustine 70mg/m\^2, Dexamethasone 20mg; Third participant received: CFZ 36mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg; Fourth participant received: CFZ 45mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg; Fifth participant and all other participants received: CFZ 56mg/m\^2, Bendamustine 90mg/m\^2, Dexamethasone 20mg. Data was collected and analyzed as one arm for this single-arm study. Additionally, presented as one arm to protect the confidentiality of the first four participants.
- id
- OG000
- title
- CFZ With Bendamustine and Dexamethasone
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- Up to 6.5 Years
- title
- Progression Free Survival (PFS)
- type
- SECONDARY
- unit Of Measure
- Months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice